<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224403</url>
  </required_header>
  <id_info>
    <org_study_id>CO-170317095828-PACT</org_study_id>
    <nct_id>NCT03224403</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy and Safety Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Consumer Inc., McNeil Consumer Healthcare Division</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Consumer and Personal Products Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate analgesic onset, efficacy, and safety of 1000 mg acetaminophen administered as
      two Test Acetaminophen 500 mg tablets (Test ACM) compared with 1000 mg acetaminophen
      administered as two commercial acetaminophen 500 mg caplets (ACM) and 400 mg ibuprofen
      administered as two commercial ibuprofen 200 mg liquid-filled capsules (IBU) in the dental
      pain model following third-molar extractions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-dose, randomized, double-blind, placebo- and active- controlled,
      parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of Test
      ACM 1000 mg compared with two commercial products over a four-hour period after third-molar
      extractions. Subjects will undergo dental extraction of three or four third molars.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Actual">April 12, 2018</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Post-operative dental pain following third molar extraction.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to confirmed perceptible pain relief</measure>
    <time_frame>0-4 hours</time_frame>
    <description>Time in minutes from dosing to perceptible pain relief as indicated on the first stopwatch. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief. The time to perceptible pain relief is confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to meaningful pain relief</measure>
    <time_frame>0-4 hours</time_frame>
    <description>Time in minutes until meaningful pain relief is achieved. Stopwatch is started after the subject takes the study medication. The subjects are instructed to stop the stopwatch when the relief from the starting pain is meaningful to them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with confirmed perceptible relief from 30 minutes to successively earlier minutes in one-minute increments (TEST ACM versus PLACEBO)</measure>
    <time_frame>30 Minutes</time_frame>
    <description>Percentage of subjects with confirmed perceptible relief at 30 minutes, 29 minutes, 28 minutes, etc. A stopwatch is started after the subject takes the study medication. The subjects are instructed to stop the stopwatch when they first begin to feel any pain relief. The perceptible pain relief is confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">664</enrollment>
  <condition>Post-operative Dental Pain</condition>
  <arm_group>
    <arm_group_label>Test acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test acetaminophen 1000 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial acetaminophen 1000 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial ibuprofen, 400 mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test acetaminophen</intervention_name>
    <description>single dose of 2 Test acetaminophen 500 mg tablets</description>
    <arm_group_label>Test acetaminophen</arm_group_label>
    <other_name>Test ACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Commercial acetaminophen</intervention_name>
    <description>single dose of 2 acetaminophen 500 mg caplets</description>
    <arm_group_label>Commercial acetaminophen</arm_group_label>
    <other_name>Commercial ACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Commercial ibuprofen</intervention_name>
    <description>Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules</description>
    <arm_group_label>Commercial ibuprofen</arm_group_label>
    <other_name>Commercial IBU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo caplets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 17 to 50 years old

          2. Weigh 100 lbs. or greater and have a body mass index (BMI) of 18 to 30 (inclusive)

          3. Dental extraction of three or four third molars

          4. Meets post-surgical pain criteria

          5. Females of childbearing age must be willing to use acceptable method of birth control

        Exclusion Criteria:

          1. Currently pregnant or planning to be pregnant or nursing a baby

          2. Known allergy to acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs)
             including aspirin, as well as hydrocodone or other opioids

          3. Inability to swallow whole large tablets or capsules

          4. Have other conditions that the investigator feels may impact subject's safety and/or
             the integrity of the study

          5. Use of pain medications 5 or more times per week

          6. Have a history of chronic tranquilizer use, heavy drinking, or substance abuse in the
             last 5 years

          7. History of endoscopically documented peptic ulcer disease or bleeding disorder in the
             last 2 years

          8. Have a positive urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Muse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research/ BB Holdings</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>YODA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

